~ Buy the BLUDIGO (indigotindisulfonate sodium) Drug Profile, 2024 PDF Report in the Report Store ~

BLUDIGO Drug Patent Profile

Which patents cover Bludigo, and when can generic versions of Bludigo launch?

Bludigo is a drug marketed by Provepharm Sas and is included in one NDA. There are three patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in BLUDIGO is indigotindisulfonate sodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indigotindisulfonate sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Bludigo

Bludigo will be eligible for patent challenges on July 8, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for BLUDIGO

International Patents:	2
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	109
Patent Applications:	2,354
Drug Prices:	Drug price information for BLUDIGO
What excipients (inactive ingredients) are in BLUDIGO?	BLUDIGO excipients list
DailyMed Link:	BLUDIGO at DailyMed

See drug prices for BLUDIGO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BLUDIGO

NDA:

216264

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BLUDIGO

Drug Class	Diagnostic Dye
Mechanism of Action	Dyes

US Patents and Regulatory Information for BLUDIGO

BLUDIGO is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting BLUDIGO

FDA Regulatory Exclusivity protecting BLUDIGO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes				Y
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes				Y
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes				Y

International Patents for BLUDIGO

When does loss-of-exclusivity occur for BLUDIGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BLUDIGO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2018116325
European Patent Office	3559121	NOUVEAU PROCÉDÉ POUR LA PRÉPARATION D'INDIGOTINDISULFONATE DE SODIUM (CARMIN D'INDIGO) (NOVEL PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE))